Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement

 

 Buy Article Permissions and Reprints

Summary

Oral dabigatran etexilate is indicated for the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement or total hip replacement. We investigated the cost-effectiveness of the 150 mg once daily (od) dose recommended for patients aged over 75 or with moderate renal impairment, from a United Kingdom National Health Service perspective. Dabigatran etexilate was compared with subcutaneous enoxaparin 40 mg od, using a decision model. Risks for VTE and bleeding were derived from subgroup analyses of the phase III trials. Dabigatran etexilate was less costly than enoxaparin; cost savings varied from £62 to £274 (base-case analyses) and were primarily due to differences in administration costs. Results were robust across a range of sensitivity analyses. Dabigatran etexilate 150 mg od is cost saving compared with enoxaparin 40 mg od in patients aged over 75 years and in patients with moderate renal impairment, with comparable efficacy and safety.

• References

• 1 The Royal College of Surgeons in England.. Publications. National Collaborating Centre for Acute Care. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. April 2007. Available at: http://www.rcseng.ac.uk/pub lications/docs/venous_thrombo.html/?searchterm=guideline. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 2 Davidson BL, Sullivan SD, Kahn SR. et al. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest 2003; 124 (Suppl. 06) 393S-6S.5.
  CrossrefPubMedGoogle Scholar
• 3 National Institute for Health and Clinical Excellence.. Clinical guidelines CG46 Venous thromboembolism (surgical). Available at: www.nice.org.uk/CG046. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 4 Warwick D, Friedman RJ, Agnelli G. et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg 2007; 89: 799-807.
  PubMedGoogle Scholar
• 5 Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001; 67: 54-56.
  CrossrefPubMedGoogle Scholar
• 6 Thorevska N, Amoateng-Adjepong Y, Sabahi R. et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-863.
  CrossrefPubMedGoogle Scholar
• 7 Family Practice Notebook.. Creatinine clearance. Available at: www.fpnotebook.com/Renal/Lab/CrtnClrnc.htm. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 8 Arixtra 2.5mg/0.5ml solution for injection, pre-filled syringe.. Summary of product characteristics. Available at: http://emc.medicines.org.uk/medicine 15123/SPC/Arixtra+2.5mg+0.5ml+solution+for+injection%2c+pre-filled+syringe. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 9 Pradaxa 110 mg hard capsules.. Summary of product characteristics. Available at: http://emc.medicines.org.uk/medicine/20760/SPC/Pradaxa+110+mg+hard + capsules. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 10 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
  CrossrefPubMedGoogle Scholar
• 11 Eriksson BI, Dahl OE, Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
  CrossrefPubMedGoogle Scholar
• 12 Ginsberg JS, Davidson BL, Comp PC. et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
  CrossrefPubMedGoogle Scholar
• 13 Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
  CrossrefPubMedGoogle Scholar
• 14 Wolowacz SE, Roskell NS, Maciver F. et al. Economic analysis of dabigatran etexilate for the prevention of venous thromboembolism following total knee and hip replacement surgery. Clin Ther 2009; 31: 1-19.
  CrossrefPubMedGoogle Scholar
• 15 National Institute for Health and Clinical Excellence.. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Technology appraisal guidance 157. Available at: http://www.nice.org.uk nicemedia/pdf/TA157Guidance.pdf. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 16 Scottish Medicines Consortium.. Dabigatran etexilate, 75mg and 110mg hard capsules (Pradaxa). No. 466/08. Available at: http://www.scottishmedicines.org.uk smc/files/dabigatran%20etexilate%20Pradaxa%20FINAL%20May%202008% 20for%20website.pdf. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 17 Dahl OE, Kurth AA, Rosencher N. et al. Efficacy and safety profile of dabigatran etexilate for the prevention of venous thromboembolism in moderately renally impaired patients after total knee or hip replacement surgery. Blood. 2008 112: 361 (Abstract 981).
  PubMedGoogle Scholar
• 18 Dahl OE, Kurth AA, Rosencher N. et al. Efficacy and safety profile of dabigatran etexilate compared with enoxaparin in primary venous thromboembolism prevention after total knee or hip replacement surgery in patients over 75 years. Blood 2008; 112: 167 (Abstract 437).
  PubMedGoogle Scholar
• 19 Clexane pre-filled syringes and multi-dose vial.. Summary of product characteristics. Available at: http://emc.medicines.org.uk/medicine/12847/SPC/Clex ane+Pre-Filled+Syringes+and+Multi-dose+Vial/. Accessed March 11, 2009.
  PubMedGoogle Scholar
• 20 Department of Health.. NHS reference costs 2005–06. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_062884. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 21 Joint Formulary Committee.. British National Formulary. Edition 57. London, British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.
  PubMedGoogle Scholar
• 22 Offord R, Lloyd AC, Anderson P, Bearne A. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci 2004; 26: 214-220.
  CrossrefPubMedGoogle Scholar
• 23 Personal Social Services Research Unit. Curtis L. Unit costs of health and social care, 2007. Available at: http://www.pssru.ac.uk/uc/uc2007contents.htm. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 24 Watts AC, Howie CR, Simpson AH. Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg 2006; 88-B: 107-110.
  CrossrefPubMedGoogle Scholar
• 25 Committee for Medicinal Products for Human Use.. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and postoperative venous thromboembolic risk, 15 November 2007. http://www.emea.europa.eu pdfs/human/ewp/70798en_fin.pdf. Accessed February 23, 2009.
  PubMedGoogle Scholar
• 26 Menzin J, Colditz GA, Regan MM. et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-764.
  CrossrefPubMedGoogle Scholar
• 27 Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. J Am Med Assoc 1987; 257: 203-208.
  CrossrefPubMedGoogle Scholar
• 28 Gordois A, Posnett J, Borris L. et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003; 1: 2167-2174.
  CrossrefPubMedGoogle Scholar
• 29 White RH, Romano PS, Zhou H. et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
  CrossrefPubMedGoogle Scholar
• 30 e-medicine. Lieberskind DS. Intracranial hemorrhage. Available at: www.emedicine.com/neuro/topic177.htm. Accessed May 23, 2007.
  PubMedGoogle Scholar
• 31 Muntz J, Scott DA, Lloyd A. et al. Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications. Int J Technol Assess Health Care 2004; 20: 405-414.
  CrossrefPubMedGoogle Scholar
• 32 Dubinsky I, Penello DR. Can specific patient variables be used to predict outcome of intracranial hemorrhage?. Am J Emerg Med 2002; 20: 26-29.
  CrossrefPubMedGoogle Scholar
• 33 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106: 2710-2715.
  CrossrefPubMedGoogle Scholar
• 34 Almeida JI, Coats R, Liem TK. et al. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg 1998; 27: 309-314.
  CrossrefPubMedGoogle Scholar
• 35 National Joint Registry for England and Wales. Drury P, Morrison J, Newell C. et al. Fourth annual clinical report: 2006 data. Available at: http://www.njrcentre. org.uk/NjrCentre/LinkClick.aspx?fileticket=8ym2zOoRfvw%3d&tabid= 86&mid=523. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 36 Office for National Statistics, UK Statistics Authority.. Deaths: age and sex, numbers and rates, 1976 onwards (England and Wales); population trends 128. Available at: http://www.statistics.gov.uk/STATBASE/Expodata/Spreadsheets D9552.xls. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 37 Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005; 8: 1-2.
  CrossrefPubMedGoogle Scholar
• 38 National Institute for Health and Clinical Excellence.. Guide to the methods of technology appraisal (reference N0515). 2004. Available at: http://www.nice.org. uk/page.aspx?o=201974. Accessed September 30, 2008.
  PubMedGoogle Scholar
• 39 Wolowacz SE, Roskell NS, Plumb JM. et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. Thromb Haemost 2009; 101: 77-85.
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Wolowacz SE, Hess N, Brennan VK. et al. Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years. Curr Med Res Opin 2008; 24: 2993-3006.
  CrossrefPubMedGoogle Scholar
• 41 Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009; 15: 377-388.
  CrossrefPubMedGoogle Scholar
• 42 Burnett RS, Clohisy JC, Wright RW. et al. Failure of the American College of Chest Physicians-1A protocol for Lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty 2007; 22: 317-324.
  CrossrefPubMedGoogle Scholar